Introduction
Pre-Exposure Prophylaxis (PrEP) The 2025 ASHM PrEP Guidelines are now published online.Last updated: August 2025 Quick access tools Download a pdf version of the guidelines or the Decision Making In PrEP tool Guidelines PDF Decision making tool Widespread availability and uptake of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) has the potential to significantly reduce HIV transmission […]
Key recommendations of the ASHM PrEP Guidelines Panel
The ASHM PrEP Guidelines Panel recommends that daily TD*/FTC should be recommended by clinicians as a crucial HIV-prevention strategy for all people who are at risk of HIV infection, that is, men who have sex with men (MSM), transgender people, heterosexual men and women, and people who inject drugs. The ASHM PrEP Guidelines Panel endorses […]
On-demand† PrEP is contraindicated in people with chronic hepatitis B infection
Of note, the Panel will continue to monitor the data on the efficacy of on-demand† PrEP for MSM who use on-demand† PrEP less frequently than fortnightly 14, 21.
PrEP safety and efficacy
For a full review of PrEP safety and efficacy please see the CDC “Pre-exposure prophylaxis for The prevention of hiv Infection in the united states– 2017 update” starting from page 16. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf
References
US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, et al. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force Recommendation Statement. JAMA 2019;321:2203-13. European AIDS Clinical Society (EACS) guidelines for the treatment of HIV-positive adults in Europe. Version 9.1, October 2018. Available at: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html (last accessed 18 July 2019). Wright […]
HIV epidemiology
Australia has a concentrated human immunodeficiency virus (HIV) epidemic, whereupon in 2018 sexual contact between men accounted for approximately 70% of new HIV diagnoses 1. During 2018, 23% of new diagnoses occurred in heterosexuals, and about one-third of these occurred where the person, or their partner came from a country with high HIV prevalence. Only 3% of […]
HIV prevention
Overall, recent declines in HIV incidence and notifications concurred with Initiatives focused on improved uptake in HIV testing and treatment with simpler HIV treatment regimens. Consequently, 74% of people living with HIV in 2017 reached viral load suppression, thereby achieving zero risk of onward HIV transmission 1. By the end of 2018, 18,530 people, of whom 99% were […]
HIV risk categories and targeted availability of PrEP in Australia
Informed by the local epidemiology of HIV, access to PrEP in Australia has been pragmatically targeted to MSM at increased risk of HIV acquisition. Criteria for increased HIV risk were originally defined based on the evidence from the Sydney-based Health in Men (HIM) study 8. The Table 3.1 summarises the main factors associated with an increased risk […]
How to access PrEP in Australia
There are three ways to access HIV pre-exposure prophylaxis (PrEP) in Australia: 1. Through the Australian health-care system For an Australian resident with a current Medicare card, PrEP can be accessed through the Pharmaceutical Benefits Scheme (PBS) at a subsidised cost. As PrEP is listed as a Schedule 85 (s85) drug, any doctor or authorised […]
Models of PrEP delivery in clinical practice
Since 2016, many accredited prescribers of s100 HIV medication, sexual health specialists, general practitioners (GPs), nurse practitioners, nurses in New South Wales, Queensland, Victoria, South Australia, Tasmania, Western Australia and the Australian Capital Territory have been involved in making pre- exposure prophylaxis (PrEP) available through clinical PrEP implementation trials and people self-importing PrEP. Since 1 […]